To meet the diagnostic criteria for cEDS, a person must meet: Major criterion 1 AND major criterion 2 OR Major criterion 1 AND three or more minor criteria Major Criteria Skin hyperextensibility and atrophic scarring Generalized joint hypermobility Minor Criteria Easy bruising Soft, doughy skin Skin fragility (or traumatic splitting) Molluscoid pseudotumors Subcutaneous spheroids Hernia (or history thereof) Epicanthal folds Complications of joint hypermobility (e.g., sprains, dislocations/subluxations, pain, flexible flatfoot) Family history of a first-degree relative who meets clinical criteria Hypermobility Spectrum Disorders (HSD) HSD in Adults Adults are diagnosed with HSD if they have symptomatic joint hypermobility that cannot be explained by other conditions
Once available, retatrutide will likely be administered as a weekly injection under the skin (subcutaneous)
The most consequential decision in any stacking protocol isn't which compounds to combine
About the Formulation This formulation combines two investigational peptide compounds: BPC-157 (Body Protection Compound-157) a synthetic peptide originally derived from a protective protein sequence identified in gastric juice and investigated in laboratory models of tissue biology and cellular signalling
Hypoxic treatment All mice were randomly assigned to the control group and each model group
However, the effects might last longer if you inhale the drug multiple times per week or if you use a high dose at one time